Endocrine Abstracts

Prostate cancer (PC) growth is androgen-dependent, hence, the mainstay for treatment is hormone-ablation therapy using anti-androgens, and/or androgen-deprivation therapies. Unfortunately, after a median time of 18 months, the cancer reappears in an androgen independent form, termed castrate-resistant PC (CRPC), which is largely fatal. To date, many molecular mechanisms have been suggested to be responsible for persistent AR signalling in CRPC. AR variants (AR-Vs), short forms...

Prostate cancer (PC) is currently the most commonly diagnosed non-cutaneous cancer affecting UK men. Androgen deprivation therapy (ADT) has traditionally been used as the gold standard treatment for advanced PC. Despite the initial response to androgen ablation, tumours relapse and become refractory to clinically approved anti-androgens, resulting in castration-resistant PC (CRPC). In CRPC, androgen receptor (AR) signalling is inappropriately restored by AR splice variants (AR...

Although new treatments for castrate-resistant prostate cancer (CRPC), such as enzalutamide and abiraterone, have shown promise, moderate response rates and development of resistance to these agents has limited their clinical effectiveness. It is therefore vital we improve our understanding of androgen receptor (AR) re-activation in advanced disease, focusing particularly on regulatory processes governing activity of AR mutants and splice variants (AR-Vs), to enable the develo...